Overcoming barriers to biosimilars in inflammatory arthritis-Reference-Cited by-同舟云学术

Overcoming barriers to biosimilars in inflammatory arthritis

Published:2019-12-23 Issue:2 Volume:16 Page:65-66
ISSN:1759-4790
Container-title:Nature Reviews Rheumatology
language:en
Short-container-title:Nat Rev Rheumatol

Author:

Kay Jonathan^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Rheumatology

Link

http://www.nature.com/articles/s41584-019-0359-7.pdf

Reference9 articles.

1. European Medicines Agency. Centrally authorised biosimilar medicines. EMA https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_medicine/field_ema_med_status/authorised-36/ema_medicine_types/field_ema_med_biosimilar/search_api_aggregation_ema_medicine_types/field_ema_med_biosimilar (2019).

2. US Food & Drug Administration. Biosimilar product information. FDA https://www.fda.gov/drugs/biosimilars/biosimilar-product-information (2019).

3. Dorner, T. & Kay, J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat. Rev. Rheumatol. 11, 713–724 (2015).

4. Goll, G. L. et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. J. Intern. Med. 285, 653–669 (2019).

5. Glintborg, B. et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann. Rheum. Dis. 78, 192–200 (2019).

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The data project: a shared approach between stakeholders of the healthcare system in definition of a therapeutic algorithm for inflammatory arthritis;Reumatismo;2023-03-21

2. The mode of delivery and content of communication strategies used in mandatory and non-mandatory biosimilar transitions: a systematic review with meta-analysis;Health Psychology Review;2021-08-30

3. The Importance of Countering Biosimilar Disparagement and Misinformation;BioDrugs;2020-07-20